BURNETT JOSEPH 4

What Happened

• Joseph M. Burnett, CEO, President and Director of ClearPoint Neuro (CLPT), had 47,407 restricted stock units (RSUs) settle on their scheduled vesting date (conversion of derivative to common stock) on 2026-03-06.
• To satisfy tax withholding, 22,709 of those shares were delivered back to the company at $10.00 per share for $227,090. That left a net issuance of 24,698 shares to the Joseph M. Burnett Trust (he is trustee).

Key Details

• Transaction date: 2026-03-06; Form 4 filed: 2026-03-10 (filed within the two-business-day rule).
• Vesting/Conversion: 47,407 RSUs converted to common shares (transaction code M).
• Tax withholding: 22,709 shares withheld (transaction code F) at $10.00/share for $227,090.
• Net shares issued to trustee: 24,698 (47,407 − 22,709). Total shares owned after the transaction is not reported on the provided data.
• Footnotes: F1—these were RSUs settled into common stock; F2—shares delivered to CLPT satisfied tax withholding; F3—the shares are owned directly by the Joseph M. Burnett Trust dated 10/20/2022 and indirectly by Mr. Burnett as trustee.

Context

• This was an RSU vesting/settlement, not an open-market purchase or sale; withholding shares for taxes is a routine administrative step and not necessarily a signal of sentiment.
• The filing shows conversion of a derivative (RSUs) into common stock and a share-withholding tax payment (similar to a cashless settlement).